Krystal Biotech stock weighs Q2 growth against USD 441 target

Published on 10/04/2026 at 22:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Krystal Biotech stock closed at USD 322.28 on October 2, 2026, while Q2 revenue reached USD 119.22 million. Analysts set a USD 365.40 average target.

KRYS, US5011471027, Illustration mit AI erstellt.

Krystal Biotech stock (ISIN US5011471027) closed at USD 322.28 on Nasdaq on October 2, 2026, down 0.93 percent from the prior close. The latest earnings picture combines USD 119.22 million of second-quarter revenue with diluted EPS of USD 1.79, while Goldman Sachs resumed coverage with a USD 441.00 price target on September 24, 2026. For investors, the central question is whether VYJUVEK growth can broaden into a larger genetic-medicine platform.

Q2 revenue reached USD 119.22 million

Krystal Biotech reported second-quarter 2026 revenue of USD 119.22 million and net income of USD 54.77 million, according to MarketBeat in its September 18, 2026 report. The companys quarterly EPS of USD 1.79 exceeded the USD 1.70 consensus, while revenue was below the USD 120.93 million estimate.

The comparison matters because profitability remains ahead of the sales trajectory. Net income increased from USD 38.33 million in the second quarter of 2025 to USD 54.77 million in the second quarter of 2026, while revenue rose from USD 96.04 million to USD 119.22 million, as reported by Markets Insider on September 24, 2026.

Analysts set a USD 365.40 midpoint

Goldman Sachs resumed coverage with a Buy rating and a USD 441.00 target on September 24, 2026, according to Markets Insider. Bank of America had raised its target from USD 392.00 to USD 400.00 while retaining a Buy rating on September 21, 2026, the same report noted.

The broader analyst view is less aggressive than the highest individual target. MarketBeat reported a Moderate Buy consensus from 13 firms, including 10 Buy ratings, one Strong Buy and two Holds, with an average 12-month target of USD 365.40 and a high target of USD 474.00. Against the October 2 price of USD 322.28, that average target is 13.7 percent higher.

Stock remains below its yearly high

Krystal Biotech carried a market capitalization of USD 9.5 billion on October 2, 2026, with 425,675 shares traded. The USD 322.28 close stood below the 52-week high of USD 382.54 and above the 52-week low of USD 178.61, leaving the stock 15.75 percent below its yearly peak.

The company describes itself as a biotechnology business developing and commercializing genetic medicines for rare diseases, with a proprietary redosable HSV vector and VYJUVEK as its lead product, according to its investor-relations profile. That mix gives the stock two measurable anchors: a profitable second quarter and a valuation still resting on pipeline expansion beyond its current commercial product.

USD 322.28 close on Nasdaq

Krystal Biotech stock closed at USD 322.28 on Nasdaq on October 2, 2026, with a daily change of negative 0.93 percent, a market capitalization of USD 9.5 billion and a 52-week range of USD 178.61 to USD 382.54.